Daniela Trisciuoglio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5749522/publications.pdf

Version: 2024-02-01

93 papers 9,098 citations

36 h-index 79698 73 g-index

98 all docs 98 docs citations 98 times ranked 19817 citing authors

#	Article	IF	CITATIONS
1	Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics, 2022, 12, 2427-2444.	10.0	12
2	The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers, 2022, 14, 6.	3.7	13
3	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410.	5.5	15
4	Effects of Structurally Different HDAC Inhibitors against <i>Trypanosoma cruzi</i> , <i>Leishmania</i> , and <i>Schistosoma mansoni</i> . ACS Infectious Diseases, 2022, 8, 1356-1366.	3.8	13
5	New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug Discovery Today, 2021, 26, 1126-1135.	6.4	15
6	Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers, 2021, 13, 3853.	3.7	4
7	First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of Medicinal Chemistry, 2021, 64, 17031-17050.	6.4	7
8	PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. International Journal of Molecular Sciences, 2021, 22, 13122.	4.1	8
9	Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem–Like Cells and Reduces Metastases through Effects on Lipid Anabolism. Cancer Research, 2020, 80, 4087-4102.	0.9	36
10	Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 103.	8.6	5
11	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983.	2.8	49
12	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	3.7	8
13	microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	4.9	30
14	Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells. Cancer Letters, 2020, 478, 133-145.	7.2	14
15	Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. , 2020, 8, e000489.		30
16	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 5612-5625.	0.9	11
17	A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting \hat{l}^3 -tubulin. Cell Division, 2019, 14, 3.	2.4	9
18	<scp>JARID</scp> 1B expression and its function in <scp>DNA</scp> damage repair are tightly regulated by mi <scp>RNA</scp> s in breast cancer. Cancer Science, 2019, 110, 1232-1243.	3.9	25

#	Article	IF	Citations
19	Histone Acetyltransferase Enzymes: From Biological Implications to Most Relevant Inhibitors. Topics in Medicinal Chemistry, 2019, , 93-122.	0.8	1
20	Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression. , 2019, , .		0
21	Abstract 2502: Targeting anti-apoptotic Bcl-2 family for cancer therapy. , 2019, , .		O
22	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis, 2018, 7, 20.	4.9	20
23	Small molecules targeted to the microtubule–Hec1 interaction inhibit cancer cell growth through microtubule stabilization. Oncogene, 2018, 37, 231-240.	5.9	18
24	Emerging Role of Histone Acetyltransferase in Stem Cells and Cancer. Stem Cells International, 2018, 2018, 1-11.	2.5	43
25	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. Journal of Experimental and Clinical Cancer Research, 2018, 37, 278.	8.6	19
26	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
27	HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene, 2018, 37, 5926-5938.	5.9	24
28	Abstract 3699: Histone deacetylase inhibitor ITF2357 induces apoptosis and increases doxorubicin cytotoxicity in preclinical models of human sarcoma., $2018,$		0
29	Abstract 5: The histone acetyltransferase inhibitor CPTH6 impairs tumor angiogenesis acting on both endothelial and cancer cells. , $2018, $, .		0
30	Metabolite profiling of ascidian Styela plicata using LC–MS with multivariate statistical analysis and their antitumor activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 614-623.	5.2	17
31	Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. Carcinogenesis, 2017, 38, 579-587.	2.8	39
32	Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene, 2017, 36, 4573-4584.	5.9	123
33	BCL-XL overexpression promotes tumor progression-associated properties. Cell Death and Disease, 2017, 8, 3216.	6.3	76
34	HMGA1 is a new biomarker of liposarcoma progression. Annals of Oncology, 2017, 28, v591.	1.2	0
35	Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. ELife, 2017, 6, .	6.0	47
36	Abstract 933: Bcl-xL overexpression promotes tumor aggressiveness. , 2017, , .		0

#	Article	IF	Citations
37	Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging, 2016, 8, 603-619.	3.1	1,014
38	miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. Molecular Carcinogenesis, 2016, 55, 2304-2312.	2.7	23
39	ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose. Cell Death and Disease, 2016, 7, e2280-e2280.	6.3	14
40	Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. European Journal of Cancer, 2016, 61, S94.	2.8	0
41	Role of bcl-2 in cancer–stroma interplay. European Journal of Cancer, 2016, 61, S43.	2.8	0
42	Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells. European Journal of Cancer, 2016, 61, S111.	2.8	0
43	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. European Journal of Cancer, 2016, 61, S111-S112.	2.8	0
44	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
45	Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene, 2016, 35, 3760-3770.	5.9	43
46	Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. Cell Death and Disease, 2016, 7, e2090-e2090.	6.3	11
47	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491.	6.4	60
48	The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget, 2016, 7, 55789-55810.	1.8	81
49	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	1.8	49
50	Abstract 4721: Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells. , 2016 , , .		0
51	3309 A novel function of Bcl-2 protein: miR-211 regulation in melanoma cells. European Journal of Cancer, 2015, 51, S667.	2.8	0
52	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget, 2015, 6, 15008-15021.	1.8	32
53	Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer. Current Medicinal Chemistry, 2015, 22, 2812-2818.	2.4	42
54	Abstract 2324: The histone acetyltransferase inhibitor CPTH6 selectively targets lung cancer stem-like cells. , 2015 , , .		0

#	Article	IF	CITATIONS
55	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Molecular Cancer, 2014, 13, 230.	19.2	51
56	822: The histone acetyltransferases inhibitor CPTH6 preferentially inhibits proliferation of patient-derived lung cancer stem cells in vitro and in vivo. European Journal of Cancer, 2014, 50, S199.	2.8	0
57	284: Evidence of a correlation between bcl-2 protein and miR-211 expression in melanoma cell lines. European Journal of Cancer, 2014, 50, S67.	2.8	0
58	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265.	6.4	102
59	Abstract 1684: Histone deacetylase inhibition enhances Pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer models. , 2014, , .		0
60	A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. Journal of Experimental and Clinical Cancer Research, 2013, 32, 72.	8.6	68
61	<i>tert</i> à€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811.	3.2	16
62	Removal of the BH4 Domain from Bcl-2 Protein Triggers an Autophagic Process that Impairs Tumor Growth. Neoplasia, 2013, 15, 315-IN37.	5.3	29
63	BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. Carcinogenesis, 2013, 34, 2558-2567.	2.8	23
64	The thiazole derivative CPTH6 impairs autophagy. Cell Death and Disease, 2013, 4, e524-e524.	6.3	28
65	Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell Death and Disease, 2013, 4, e639-e639.	6.3	38
66	CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells. Clinical Cancer Research, 2012, 18, 475-486.	7.0	47
67	965 Modulation of Autophagic Flux by CPTH6, a Gcn5/pCAF Histone Acetyltransferase Inhibitor With Antitumoral Activity. European Journal of Cancer, 2012, 48, S232.	2.8	0
68	LMNA Knock-Down Affects Differentiation and Progression of Human Neuroblastoma Cells. PLoS ONE, 2012, 7, e45513.	2.5	40
69	Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death and Differentiation, 2011, 18, 1024-1035.	11.2	53
70	Bcl-2 Regulates HIF- $1\hat{l}\pm$ Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90. PLoS ONE, 2010, 5, e11772.	2.5	72
71	406 The BH4 domain is required for proangiogenic function of bcl-2 protein. European Journal of Cancer, Supplement, 2010, 8, 104.	2.2	0
72	478 Bcl-2 regulates HIF-1a protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90b. European Journal of Cancer, Supplement, 2010, 8, 153.	2.2	2

#	Article	IF	Citations
73	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Structural and Molecular Biology, 2009, 16, 1086-1093.	8.2	182
74	Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. European Journal of Cancer, 2009, 45, 2618-2627.	2.8	121
75	Involvement of nuclear factorâ€kappa B in bclâ€xLâ€induced interleukin 8 expression in glioblastoma. Journal of Neurochemistry, 2008, 107, 871-882.	3.9	41
76	Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells. Cancer Research, 2008, 68, 285-291.	0.9	69
77	Induction of Apoptosis in Human Cancer Cells by Candidaspongiolide, a Novel Sponge Polyketide. Journal of the National Cancer Institute, 2008, 100, 1233-1246.	6.3	39
78	Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression. Molecular Cancer Research, 2007, 5, 761-771.	3.4	41
79	Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. Cancer Research, 2006, 66, 5549-5554.	0.9	314
80	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death and Differentiation, 2005, 12, 1429-1438.	11.2	124
81	Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. Journal of Cellular Physiology, 2005, 205, 414-421.	4.1	69
82	Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells. Molecular Biology of the Cell, 2005, 16, 4153-4162.	2.1	88
83	Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7747-7756.	7.0	50
84	bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation. Journal of Biological Chemistry, 2004, 279, 6737-6745.	3.4	60
85	Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions. Neoplasia, 2004, 6, 513-522.	5.3	29
86	Crosstalk between VEGF and Bcl-2 in Tumor Progression and Angiogenesis., 2004,, 26-39.		0
87	Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene, 2003, 22, 8441-8447.	5.9	59
88	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	2.3	132
89	Bclâ€2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIFâ€1 mediated transcriptional activity. FASEB Journal, 2002, 16, 1453-1455.	0.5	117
90	Phototoxic effect of fluoroquinolones on two human cell lines. Toxicology in Vitro, 2002, 16, 449-456.	2.4	21

#	Article	IF	CITATIONS
91	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. European Journal of Cancer, 2002, 38, 2455-2462.	2.8	32
92	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. Journal of Cellular Biochemistry, 2001, 83, 473-483.	2.6	14
93	relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. British Journal of Cancer, 2001, 85, 1914-1921.	6.4	51